Vivos Therapeutics, Inc.: 5%+ holders

As of November 8, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Vivos Therapeutics, Inc. The largest reported stake is V-Co Investors 3 LLC's, at 19.9%. 7 filings are on record since July 14, 2025 (Schedule 13D, April 2, 2026).

Streeterville Capital LLC also filed stake reports on 29 other companies ↓

Sell to companies like Vivos Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Event date 2026-09-03 · Holder: Streeterville Capital LLC · Percent: 0.6% · Shares: 122,963 · SCHEDULE 13G/A
• Filing 2026-08-14 · Reporting person: Armistice Capital, LLC · Sole voting: 0 · Shared voting: 729,755 · Sole dispositive: 0 · Shared dispositive: 729,755 · SCHEDULE 13G/A, 2026-08-14
• Filed 2026-08-11 · Holder: Streeterville Capital LLC · Percent: 9.3% · SCHEDULE 13G
• Filing 2026-07-15 · Reporting person: V-CO Investors LLC · Sole voting: 0 · Shared voting: 514,498 · Sole dispositive: 0 · Shared dispositive: 514,498 · SCHEDULE 13D, 2026-07-15
• Filed 2026-05-15 · Holder: Armistice Capital, LLC · Percent: 8.27% · SCHEDULE 13G

Vivos Therapeutics, Inc. has 7 Schedule 13D or 13G filings on record since 2025-07-14. 3 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Vivos Therapeutics, Inc. and the warning signs.

See Vivos Therapeutics, Inc.'s free Snapshot Watch Vivos Therapeutics, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Vivos Therapeutics, Inc. and the records around it.

Vivos Therapeutics, Inc. elsewhere on the record

• Acquisition Oct 2026
• Leadership changes Aug 2026
• Who owns it

Companies that share a holder

• Streeterville Capital LLC also filed stake reports on 29 other companies: Professional Diversity Network, Inc. (Oct 2026), Solowin Holdings, Ltd. (Oct 2026), Empery Digital Inc. (Aug 2026)
• Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)

Want the whole picture on Vivos Therapeutics, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Vivos Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Vivos Therapeutics, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   9 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Vivos Therapeutics, Inc. by CUSIP 92859E207 and gives its principal executive office as 7921 SOUTHPARK PLAZA, SUITE 210, LITTLETON, CO 80120 (SCHEDULE 13G/A, 2026-09-03).

Source of funds (Item 3)

Available net assets were used to purchase the shares referred to in Item 4 of this Schedule 13D. The total amount of the funds used to make the purchases was $1,600,000 (the "Subscription Amount"). The Subscription Amount included the conversion and satisfaction in full of $1,100,000 pursuant to a Convertible Promissory Note, dated May 7, 2026, between the Issuer and V-Co 4 (the "Convertible Promissory Note"). The Convertible Promissory Note included an original issue discount of $100,000.V-Co Investors 4 LLC, SCHEDULE 13D, 2026-07-15

Purpose of Transaction (Item 4)

V-Co Investors 3 LLC

The Reporting Person's purpose of acquiring these securities is for investment purposes. The Reporting Person intends to engage, or has engaged, in discussions with the Issuer and its management and/or board of directors regarding the Issuer's financial performance, strategic direction, operational matters, and corporate governance practices. On March 31, 2026, the Issuer and V-Co 3 entered into a Securities Purchase Agreement where the Issuer sold to V-Co 3 in a private placement: (i) 1,353,625 shares of Common Stock ("PIPE Common Stock"), (ii) a Series A Common Stock Purchase Warrant ("Series A Warrant") to purchase up to 1,783,582 shares of Common Stock ("Warrant Shares"), (iii) a Series B Common Stock Purchase Warrant ("Series B Purchase Warrant" and together with the Series A Warrant, the "Common Stock Warrants") to purchase up to 1,783,582 Warrant Shares and (iv) a Pre-Funded Warrant ("Pre-Funded Warrant") to purchase up to 429,957 shares of Common Stock ("PFW Shares," together with the PIPE Common Stock and Warrant Shares, the "Shares"). In compliance with the listing rules of the Nasdaq Stock Market LLC, V-Co 3 purchased the Shares at a purchase price of $1.34 per share. The Series A Warrant is immediately exercisable with a two-year term from the date of purchase and has an exercise price of $1.09 per share. The Series B Warrant is immediately exercisable with a five-year term from the date of purchase and has an exercise price of $1.09 per share. Similarly, the …The first part of Item 4 of the SCHEDULE 13D filed 2026-04-02; the filing has the rest

V-Co Investors 4 LLC

The Reporting Person's purpose of acquiring these securities is for investment purposes. The Reporting Person intends to engage, or has engaged, in discussions with the Issuer and its management and/or board of directors regarding the Issuer's financial performance, strategic direction, operational matters, and corporate governance practices. On June 30, 2026, the Issuer and V-Co 4 entered into a Securities Purchase Agreement where the Issuer sold to V-Co 4 in a private placement: (i) 2,749,330 shares of Series A Convertible Preferred Stock ("Convertible Preferred Stock"), and (ii) a Common Stock Purchase Warrant ("Common Stock Warrant") to purchase up to 2,749,330 shares of Common Stock ("Warrant Shares"). In compliance with the listing rules of the Nasdaq Stock Market LLC, V-Co 4 purchased the Shares at a purchase price of $0.582 per share. The Common Stock Warrant is immediately exercisable with a five-year term from the date of purchase and has an exercise price of $0.456 per share. V-Co 4 is prohibited from converting such Convertible Preferred Stock and exercising such Common Stock Warrants if it results in V-Co 4 or its affiliates owning in excess of 19.99% of the then outstanding Common Stock of the Issuer. Accordingly, for purposes of this Schedule 13D, only 86,979 of the shares of Common Stock underlying the Convertible Preferred Stock and Common Stock Warrant purchased by V-Co 4 in the private placement are deemed to be beneficially owned by V-Co 4. See Item 5 …The first part of Item 4 of the SCHEDULE 13D filed 2026-07-15; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Vivos Therapeutics, Inc.

Who owns Vivos Therapeutics, Inc.?

On this page, 3 holders' latest ownership filings report 5% or more of Vivos Therapeutics, Inc.: V-Co Investors 3 LLC (19.9%, Schedule 13D, filed 2026-04-02), V-Co Investors 4 LLC (19.9%, Schedule 13D, filed 2026-07-15) and Dawei Luo (8.52%, Schedule 13G, filed 2025-07-14).

Who are the largest shareholders of Vivos Therapeutics, Inc.?

By the share each holder's latest filing reports, the largest holders of Vivos Therapeutics, Inc. on this page are V-Co Investors 3 LLC (19.9%), V-Co Investors 4 LLC (19.9%) and Dawei Luo (8.52%).

When did V-Co Investors 3 LLC buy into Vivos Therapeutics, Inc.?

The filings give report dates, not purchase dates. The earliest filing from V-Co Investors 3 LLC on this page is the Schedule 13D, filed 2026-04-02, reporting 19.9%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Vivos Therapeutics, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Vivos Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Vivos Therapeutics, Inc. is mentioned again
• Find former Vivos Therapeutics, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes